title: Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Piccolo
authors.forename: Dik
authors.initials: D
authors.lastname: Heg
authors.forename: Anna
authors.initials: A
authors.lastname: Franzone
authors.forename: Marco
authors.initials: M
authors.lastname: Roffi
authors.forename: David
authors.initials: D
authors.lastname: Tüller
authors.forename: André
authors.initials: A
authors.lastname: Vuilliomenet
authors.forename: Olivier
authors.initials: O
authors.lastname: Muller
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cook
authors.forename: Daniel
authors.initials: D
authors.lastname: Weilenmann
authors.forename: Christoph
authors.initials: C
authors.lastname: Kaiser
authors.forename: Peiman
authors.initials: P
authors.lastname: Jamshidi
authors.forename: Juan F
authors.initials: JF
authors.lastname: Iglesias
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Thomas
authors.initials: T
authors.lastname: Pilgrim
mesh_terms: D020341:Absorbable Implants; D002986:Clinical Trials as Topic; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D009203:Myocardial Infarction; D062645:Percutaneous Coronary Intervention; D011108:Polymers; D020123:Sirolimus / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011108:Polymers; D000068338:Everolimus; D020123:Sirolimus